FOR IMMEDIATE RELEASE
Tokyo-Based EPS Responds to Growing Customer Demand for Medidata Rave in Asia Pacific
NEW YORK, NY and TOKYO, JAPAN – October 2, 2007 – Medidata Solutions, a global provider of electronic clinical data capture (EDC), management and reporting solutions, today announced the start of its ASPire to Win™ partnership with EPS, one of Japan’s largest contract research organizations (CRO). As the first ASPire to Win partner in Japan, EPS can now easily incorporate Medidata Rave® into their existing offerings to manage electronic clinical trial data for biopharmaceutical and medical device companies around the world.
Established in 1991, EPS provides a full range of professional services in clinical trials for drug development to pharmaceutical companies in Japan. EPS selected Medidata Rave due to increased sponsor demand for the product’s robust functionality, ease-of-use and integration capabilities. By participating in Medidata’s ASPire to Win Program, a non-exclusive application service provider (ASP) partnership and business model, EPS can offer Medidata Rave in-house and create new services revenue around the implementation of this industry-leading technology.
“At EPS, we have trust in Medidata due to the company’s growing market presence in Japan and globally. We respect the company’s ability to support global studies through Rave’s multi-lingual capabilities and manage clinical trial data in a single, secure and scalable system,” said Hisao Imamura, Senior Manager in the office of the president at EPS. “We look forward to working with Medidata to provide the strongest EDC and CRO services available to customers in the demanding Japan market.”
Since the trend toward clinical research outsourcing is still new in Japan, there are many challenges to address to meet the increasing customer needs for both quality and quantity of services. Through implementing Medidata Rave, EPS will accelerate their new business of global studies. Additionally, with the greater ability to streamline clinical data collection and management for its clients, the Rave certification will allow EPS to continue to expand their offerings for sponsors.
“As one of Japan’s largest CROs, EPS maintains a proven ability to contribute to better pharmaceutical product development, and the company’s decision to implement Medidata Rave into their existing EDC solution will help facilitate the constant growth of Rave in Japan—and around the globe,” said Tarek Sherif, CEO at Medidata Solutions. “We look forward to furthering the success of EPS’ new and existing customers through Medidata’s ASPire to Win Program.”
About EPS
EPS is a CRO (contract research organization) that operates clinical trials precisely, rapidly and objectively. We provide a full range of professional services in Japan, China and Southeast Asia. We are supporting entire drug development with SMO, IT and global business. For more information, please visit www.eps.co.jp.
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market—on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com